Zai Lab Limited ( NASDAQ: ZLAB) said on Monday that it received U.S. FDA fast track designation for its antibody-drug ...

Jan. 9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point ... with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring ...

A new study published in the Annals of Surgical Oncology revealed that individuals with little muscle mass, segmentectomy ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

Almost a third of Americans are more than a year behind in cancer screening, more than half of them because of out-of-pocket ...

Basel: Roche has announced that the FDA has approved the VENTANA MET (SP44) RxDx Assay, the first companion diagnostic ...